{"id":"W1814699096","doi":"10.1016/j.ctrv.2004.08.002","title":"Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.","year":2004,"lang":"en","type":"letter","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Gefitinib; Medicine; Carboplatin; Paclitaxel; Lung cancer; Chemotherapy; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Cancer; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001246814,0.0003132203,0.001721479,0.0003788235,0.0007962468,0.0007693553,0.0004215174,0.006538305,0.00564177],"category_scores_gemma":[0.006467468,0.0001718835,0.001021508,0.0005402566,0.0004916405,0.0008104823,0.0002685315,0.003045108,0.002444633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001413378,"about_ca_system_score_gemma":0.0007990158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001859429,"about_ca_topic_score_gemma":0.006921879,"domain_scores_codex":[0.999143,0.000272284,0.0001011821,0.00009659019,0.0002226628,0.0001642992],"domain_scores_gemma":[0.997976,0.001208307,0.0002116145,0.00004387111,0.0002409625,0.0003192183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.007932032,0.0002888511,0.022985,0.0009970178,0.000482382,0.01199439,0.0001861167,0.0003627307,0.003457135,0.001477554,0.6500162,0.2998206],"study_design_scores_gemma":[0.008840526,0.006486249,0.09236597,0.001436707,0.00169951,0.02583051,0.0004676285,0.001631676,0.002900948,0.005463522,0.8527438,0.0001329384],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.06086035,0.07834439,0.0003028211,0.8030335,0.02061971,0.00008109231,0.001143321,0.0002154438,0.03539935],"genre_scores_gemma":[0.3479258,0.05097986,0.0007114542,0.4955959,0.07821374,0.0001764536,0.0008246801,0.00009931347,0.02547283],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.006538305,"threshold_uncertainty_score":0.01887357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01463295194877606,"score_gpt":0.3232133757697233,"score_spread":0.3085804238209472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}